Empower Sponsor Success with Insights from Sites

The current oncology and hematology drug development pipeline features a wide array of large molecule therapeutics. As a result, clinical trial protocols have grown more complex, requiring sponsors, CROs, and research sites to tackle a variety of challenges that were less common with older, more traditional therapies.

Do you leverage a quality-first mindset as you evaluate clinical trial technology? When you evaluate eCOA and IRT solutions, quality cannot be ignored, as choosing poorly can lead to data integrity issues, regulatory roadblocks, and costly delays that can postpone potentially lifesaving treatments. How can you ensure your clinical trial technology partner prioritizes quality throughout the clinical research journey? This checklist is your guide to choosing a quality-first solution.

As drug development costs continue to escalate, sponsors are incentivized to find less expensive approaches to develop their assets. FSP models provide increased operational and resourcing flexibility and different pricing plans in comparison to traditional full-service CRO offerings.

Large CROs operate with a one-size-fits-all approach. When this no longer worked for a late-stage clinical biopharmaceutical company, they turned to Catalyst Flex to design a tailored solution to meet the safety needs of this rescue study.